News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vectura Group plc Positive Interim Results for Parkinson’s Disease Drug
October 31, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON - Vectura Group has announced positive results for an interim study of its VR040 drug, a product designed to treat periods of complete or partial immobility in patients with Parkinson's disease.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
March 2, 2026
·
2 min read
·
Tristan Manalac
Insights
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
February 26, 2026
·
1 min read
·
Jennifer Smith-Parker
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
·
2 min read
·
Annalee Armstrong
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
·
2 min read
·
Tristan Manalac
